These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18826867)

  • 1. Evaluating average bioequivalence using methods for high variability drugs: a case study.
    Sanchez MP; Gomez C; Carrasco JL; Ocana J; von Plessing C; Godoy CG; Reinbach R; Godoy R
    Int J Clin Pharmacol Ther; 2008 Oct; 46(10):527-37. PubMed ID: 18826867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations.
    Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; Yánez C; López de Ocáriz A; Solinís MA; Pedraz JL
    Arzneimittelforschung; 2003; 53(5):321-9. PubMed ID: 12854359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters.
    Wolf-Coporda A; Lovrić Z; Huić M; Francetić I; Vrhovac B; Plavsić F; Skreblin M
    Int J Clin Pharmacol Res; 1996; 16(4-5):83-8. PubMed ID: 9172005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Effect on Average Bioequivalence.
    Ibarra M; Vázquez M; Fagiolino P
    Clin Ther; 2017 Jan; 39(1):23-33. PubMed ID: 28034518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs.
    Boddy AW; Snikeris FC; Kringle RO; Wei GC; Oppermann JA; Midha KK
    Pharm Res; 1995 Dec; 12(12):1865-8. PubMed ID: 8786957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence and intrasubject variability.
    Liu JP
    J Biopharm Stat; 1991; 1(2):205-19. PubMed ID: 1844697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and in vitro examination of furosemide containing suppositories and preliminary experiences of their clinical use.
    Regdon G; Fazekas T; Regdon G; Selmeczi B
    Pharmazie; 1996 Feb; 51(2):116-9. PubMed ID: 8720807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.
    Almeida S; Filipe A; Neves R; Pinho C; Pedroso P; Castillo A; Trabelsi F
    Arzneimittelforschung; 2011; 61(1):32-9. PubMed ID: 21355444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach for outliers in a bioavailability/bioequivalence study.
    Liao JJ
    J Biopharm Stat; 2007; 17(3):393-405. PubMed ID: 17479389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of food on the absorption of frusemide and bumetanide in man.
    McCrindle JL; Li Kam Wa TC; Barron W; Prescott LF
    Br J Clin Pharmacol; 1996 Dec; 42(6):743-6. PubMed ID: 8971430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical issues in bioequivalence [correction of bioequivalance].
    Senn S
    Stat Med; 2001 Sep 15-30; 20(17-18):2785-99. PubMed ID: 11523083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations.
    Hamidi M; Shahbazi MA; Azimi K
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):149-56. PubMed ID: 21193005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusion complexation of furosemide in cyclodextrins. Part 2: Implication on bioavailability.
    Ammar HO; Ghorab M; Emara LH; el-Nahhas SA; Makram TS
    Pharmazie; 1999 Mar; 54(3):207-10. PubMed ID: 10192107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative bioavailability of two irbesartan/hydrochlorothiazide tablet formulations in Indonesian healthy subjects.
    Sasongko L; Harahap Y; Prasaja B; Lusthom W; Setiawan EC; Meliala RS; Lipin
    Arzneimittelforschung; 2010; 60(12):749-53. PubMed ID: 21265466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.